Back to discover

Protein / target

Uracil-DNA glycosylase

Encoded byUNGP13051Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Uracil DNA N-glycosylase

Strongest disease association

Food Hypersensitivity

Via encoding gene UNG · Genetic evidence · score 0.42

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Uracil-DNA glycosylase that hydrolyzes the N-glycosidic bond between uracil and deoxyribose in single- and double-stranded DNA (ssDNA and dsDNA) to release a free uracil residue and form an abasic (apurinic/apyrimidinic; AP) site.

View complete UniProt function annotation

Uracil-DNA glycosylase that hydrolyzes the N-glycosidic bond between uracil and deoxyribose in single- and double-stranded DNA (ssDNA and dsDNA) to release a free uracil residue and form an abasic (apurinic/apyrimidinic; AP) site. Excises uracil residues arising as a result of misincorporation of dUMP residues by DNA polymerase during replication or due to spontaneous or enzymatic deamination of cytosine (PubMed:12958596, PubMed:15967827, PubMed:17101234, PubMed:22521144, PubMed:7671300, PubMed:8900285, PubMed:9016624, PubMed:9776759). Mediates error-free base excision repair (BER) of uracil at replication forks. According to the model, it is recruited by PCNA to S-phase replication forks to remove misincorporated uracil at U:A base mispairs in nascent DNA strands. Via trimeric RPA it is recruited to ssDNA stretches ahead of the polymerase to allow detection and excision of deaminated cytosines prior to replication. The resultant AP sites temporarily stall replication, allowing time to repair the lesion (PubMed:22521144). Mediates mutagenic uracil processing involved in antibody affinity maturation. Processes AICDA-induced U:G base mispairs at variable immunoglobulin (Ig) regions leading to the generation of transversion mutations (PubMed:12958596). Operates at switch sites of Ig constant regions where it mediates Ig isotype class switch recombination. Excises AICDA-induced uracil residues forming AP sites that are subsequently nicked by APEX1 endonuclease. The accumulation of staggered nicks in opposite strands results in double strand DNA breaks that are finally resolved via non-homologous end joining repair pathway (By similarity) (PubMed:12958596)

Subcellular location

MitochondrionNucleus
Domains and Gene Ontology detail (11)

Gene Ontology

  • Cmitochondrion
  • Cnucleoplasm
  • Cnucleus
  • Fdamaged DNA binding
  • Fribosomal small subunit binding
  • Furacil DNA N-glycosylase activity
  • Pbase-excision repair
  • Pbase-excision repair, AP site formation via deaminated base removal
  • Pdepyrimidination
  • Pnegative regulation of apoptotic process
  • Psingle strand break repair

313 aa · 35 kDa · 2 isoforms

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene UNG

Gene-level evidence surfaced through the gene UNGthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Food Hypersensitivity
0.42Limited support

Genetic evidence dominant · Open Targets 0.25

Common variable immunodeficiency
0.22Preliminary

Animal model evidence dominant · Open Targets 0.07 · no direct causal or clinical evidence

Neoplasms
0.13Preliminary

Literature evidence dominant · Open Targets 0.11 · no direct causal or clinical evidence

Infections
0.12Preliminary

Literature evidence dominant · Open Targets 0.10 · no direct causal or clinical evidence

Lymphoma
0.08Preliminary

Literature evidence dominant · Open Targets 0.07 · no direct causal or clinical evidence

View evidence synthesis (5)
Food HypersensitivityLimited support
0.42
agreement 0.300.54
Genetic100%

Open Targets aggregate 0.25 · 1 independent evidence family

Common variable immunodeficiencyPreliminary
0.22
agreement 0.040.39
Animal model95%Literature5%

Open Targets aggregate 0.07 · 2 independent evidence families · no direct causal or clinical evidence

NeoplasmsPreliminary
0.13
agreement 0.000.41
Literature100%

Open Targets aggregate 0.11 · 1 independent evidence family · no direct causal or clinical evidence

InfectionsPreliminary
0.12
agreement 0.000.39
Literature100%

Open Targets aggregate 0.10 · 1 independent evidence family · no direct causal or clinical evidence

LymphomaPreliminary
0.08
agreement 0.000.36
Literature100%

Open Targets aggregate 0.07 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Food Hypersensitivity0.25
Neoplasms0.11
Infections0.10
Lymphoma0.07
Common variable immunodeficiency0.07

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and med-quality pocket) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (5)
SM · Structure with LigandSM · Med-Quality PocketPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.